MRK - Merck & Co., Inc.
| Previous Close | 70.78 |
| Open | 70.85 |
| Bid | 0.00 x 4000 |
| Ask | 0.00 x 900 |
| Day's Range | 70.52 - 71.38 |
| 52 Week Range | 52.83 - 71.58 |
| Volume | 6,460,371 |
| Avg. Volume | 8,129,498 |
| Market Cap | 187.896B |
| Beta | 1.06 |
| PE Ratio (TTM) | 145.67 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.92 (2.70%) |
| Ex-Dividend Date | 2018-09-14 |
| 1y Target Est | N/A |
Market Realist•8 hours agoExploring Idexx Laboratories’ Operational Performance
Idexx Laboratories (IDXX) incurred general and administrative expenses of $61.08 million in the second quarter, compared with $55.46 million in the second quarter of 2017. Its sales and marketing expenses increased from $87.69 million in the second quarter of 2017 to $96.25 million in the second quarter due to increased personnel-related costs. Its research and development expenses increased from $26.9 million in the second quarter of 2017 to $29.51 million in the second quarter.
Market Realist•8 hours agoHow Idexx Laboratories Is Positioned in 2018
Idexx Laboratories’ (IDXX) products and services cater to the companion animal, veterinary, livestock, poultry, dairy, and water testing markets. The company also sells portable electrolytes and blood gas analyzers. So far in 2018, Idexx Laboratories stock has generated more than 50.0% returns for investors.
- Market Realist•16 hours ago
Allergan’s First Medical Aesthetics Innovation Center in China
Allergan (AGN) announced on September 19 that it plans to build its first Medical Aesthetics Innovation Center in the High-Tech Zone in Chengdu, China. The Medical Aesthetics and Innovation Center is expected to have a sophisticated training center for the healthcare professionals in the medical aesthetics field. For its medical aesthetics customers, the Center plans to feature an education and product experience space.
Market Realist•17 hours agoJ&J Files for US Approval of Cancer Drug Erdafitinib
On September 18, Johnson & Johnson (JNJ) announced that it had submitted a new drug application to the FDA for its investigational drug, erdafitinib, for the treatment of locally advanced or metastatic UC (urothelial cancer) in patients with certain FGFR (fibroblast growth factor receptor) genetic alterations. The application is based on the findings of BLC2001, a Phase 2 study. Erdafitinib, one of the company’s key pipeline products, is expected to drive growth. The diagram below shows some of J&J’s recent pharmaceutical launches and filings expected over the next few years. In March, J&J received breakthrough therapy designation for erdafitinib from the FDA.
- Market Realist•19 hours ago
Allergan’s Stock Price Performance in September
Allergan (AGN) is a specialty pharmaceutical company that develops a variety of products through internal programs as well as in collaboration with other companies. Allergan’s stock price has decreased nearly 0.6% to its closing price of $191.31 on September 21 compared to its closing price on September 20.
- Market Realist•yesterday
A Look at Johnson & Johnson’s Valuation This Month
On September 23, Johnson & Johnson (JNJ) had a market capitalization of $376.8 billion, and its stock closed ~0.63% higher than the day prior. J&J was trading at a forward PE ratio of 16.8x, while its last-12-month PE ratio was 26.1x. Generally, a high forward PE is a sign of an overvalued or high-growth stock.
- American City Business Journals•yesterday
OpGen signs deal with New York health department to research superbugs
The Maryland biotech hopes its new superbug contract with Merck and the state of New York puts it on the national map for drug-resistant disease research.
- Bloomberg•2 days ago
Roche Left Seeking a Niche as Merck Dominates Lung-Cancer Market
Roche Holding AG is starting to look more like a niche player in the hottest new field in oncology, as lung-cancer study results unveiled on Monday failed to meet the benchmark set by U.S. rival Merck & Co. It’s still unclear whether and how much Roche’s drug Tecentriq can extend the lives of patients with the most common type of lung cancer when added to chemotherapy, the Basel, Switzerland-based company said in a patient trial presented Monday at the World Conference on Lung Cancer in Toronto. The results mean Roche will need to concentrate for now on less common -- and less lucrative -- types of tumors.
- American City Business Journals•2 days ago
Merck subsidiary plans $48M investment, 115 jobs in Albany area over five years
ILÚM will partner with health care company OpGen Inc., the New York Department of Health and the Wadsworth Center on a new "research program to detect, track and manage antimicrobial-resistant infections at healthcare institutions statewide."
- Simply Wall St.•2 days ago
With An ROE Of 4.2%, Has Merck & Co Inc’s (NYSE:MRK) Management Done Well?
This article is intended for those of you who are at the beginning of your investing journey and want to start learning about core concepts of fundamental analysis on practicalRead More...
- Zacks•5 days ago
Galectin's GR-MD-02 Positive in Phase Ib Study With Keytruda
Galectin Therapeutics (GALT) posts favorable results from a phase Ib study on GR-MD-02 combined with Merck's Keytruda for treating metastatic melanoma.
Market Realist•5 days agoNew Indications Are Expected to Drive Future Growth of Keytruda
According to Goldman Sachs analyst Jami Rubin, Merck’s (MRK) Keytruda can earn annual revenues as high as $16.0 billion by 2025. Credit Suisse expects the drug to report peak sales of about $10.0 billion by 2023. According to Trefis estimates, Keytruda is expected to attain peak sales of ~$8.0 billion going forward.
- Market Realist•5 days ago
Keytruda Is a Major Growth Asset for Merck in 2018
In the first half of the year, Keytruda accounted for 15.27% of Merck’s (MRK) total revenues. Keytruda earned more than 40.0% of its total sales from international markets, despite the company having launched the drug only as a monotherapy and not as a combination regimen in these markets. By the end of the first half of the year, Keytruda was earning 60.0%–65.0% of its revenues from sales to lung cancer patients.
Market Realist•5 days agoWhy Merck Stock Has Risen 28.2% Year-to-Date
Merck (MRK) stock has risen from $54.93 on January 2 to $70.42 on September 18—a 28.2% increase year-to-date. The performance of Merck stock has been closely related to the sales, clinical trial outcomes, and regulatory decisions for the company’s leading immuno-oncology drug, Keytruda. Approved in 13 indications and eight tumor types, Keytruda reported sales of $1.7 billion in the second quarter.
- Motley Fool•5 days ago
How Do Drugs Compete Against Each Other?
Investors can keep an eye on these four factors to tell which drugs will out-compete the rest.
- American City Business Journals•5 days ago
Flexible labs, co-working space: Big Pharma is rethinking real estate
At an industry event Thursday, representatives from both Merck & Co. and Bristol-Myers Squibb stressed the importance of flexibility in real-estate assets.
- Zacks•6 days ago
Merck or Pfizer: Which is the Better Large-Cap Pharma Stock?
In the Large-cap pharma sector, Merck (MRK) and Pfizer (PFE) are two of the biggest names.
- Market Realist•6 days ago
Pharma Stocks: GlaxoSmithKline’s Revenue Trend and 2018 Estimates
GlaxoSmithKline reported a nearly flat top line at 7.3 billion pounds, including a 4% rise in operating revenue offset by a 4% negative foreign exchange impact. GlaxoSmithKline’s business is divided into three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare.
- MarketWatch•6 days ago
Galectin stock lifts 15% premarket on early cancer combination trial results
Galectin Therapeutics Inc. shares surged 15% in Thursday premarket trade after the company said that combining its therapy, GR-MD-02, with Keytruda, Merck & Co.'s leading cancer therapy, appeared to have better results for patients with advanced melanoma than Keytruda alone. Notably, though, results were preliminary, based on data from an early-stage, phase 1b clinical trial, and integrated results from two earlier groups of patients on lower doses of GR-MD-02 with a third, higher-dose group. Galectin said that of 14 patients across the three groups, seven had reductions in cancer tumor size, or an objective response rate of 50%. Meanwhile, Keytruda alone has response rate that ranges between 21% to 39%, noted Dr. Brendan Curti, the trial's principal investigator and the director of the Providence Cancer Institute's melanoma program. Of the trial's 14 patients, nine had their cancer improve or remain stable, or a disease control rate of 64%. The phase 1b trial also enrolled six patients with head and neck cancer, for whom a 33% objective response rate and 67% disease control rate were observed. Curti said he and others were "very encouraged" by the melanoma results, and noted that results in both cancers were better than expected for Keytruda on its own. The trial will move forward in both areas, he said, and they plan to include more patients. Galectin shares have dropped nearly 24% over the last three months, compared with a 5.1% rise in the S&P 500 and a 7.1% rise in the Dow Jones Industrial Average .
Market Realist•6 days agoHow Accenture’s Partnership with Merck Could Be Helpful
Accenture (ACN) has teamed up with Merck & Co. (MRK), one of the leading pharmaceutical giants outside the United States, to drive production, effectiveness, and innovation in the initial stages of drug development. Both companies have included Amazon’s (AMZN) AWS (Amazon Web Services) cloud computing, The involvement of the leading public cloud service provider should allow MSD to introduce a cloud-based informatics research platform to support the life sciences industry related to drug manufacturing.
- GuruFocus.com•6 days ago
Merck & Co Inc (MRK) Chairman, President & CEO Kenneth C Frazier Sold $19. ...
Chairman, President & CEO of Merck & Co Inc (NYSE:MRK) Kenneth C Frazier sold 279,851 shares of MRK on 09/18/2018 at an average price of $70.08 a share.
Market Realist•7 days agoCan Accenture Meet Its Operating Margin Guidance in Q4 2018?
Accenture (ACN) has forecast its operating margin for fiscal 2018 at 14.8%, which would be higher than its fiscal 2017 margin of 12.9%. In the past five quarters, it mostly sustained a double-digit operating margin. In the chart below, you can see its GAAP operating margin trend in the last five quarters.
- Market Realist•7 days ago
Pharma Stocks in Review: A Valuation Comparison
In this article, we’ll compare the valuations of Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).
- Zacks•7 days ago
Accenture, Merck & Amazon AWS Partner for Cloud Platform
Accenture's (ACN) latest partnership is likely to boost its Products segment.
- MarketWatch•7 days ago
Health care ETF surges toward record in a broad sector rally
The SPDR Health Care Select Sector ETF rose 0.7% toward a record high in afternoon trade Tuesday, with 55 of its 63 equity components gaining ground. Among the ETF's (XLV) members which are also Dow Jones Industrial Average components, Pfizer Inc.'s stock shot up 1.5%, putting it on track to close at the highest level since December 2001. Also, shares of Johnson & Johnson gained 0.6% toward an eight-month high, Merck & Co. Inc. tacked on 0.4% to sit just shy of its 17-year high reached last Thursday, and UnitedHealth Group Inc. slipped 0.1% and was 2.2% below its Sept. 6 record close of $269.65. The XLV's biggest gainer was Abiomed Inc.'s stock , which rallied 2.7%, while its biggest decliner was AbbVie Inc.'s stock , which shed 2.1% after California sued the company alleging the payment of illegal kickbacks. The XLV has rallied 11% over the past three months, while the Dow has tacked on 5.2%.
